by nms-sync | Jul 19, 2022 | News
Nerviano Medical Sciences S.r.l., a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, recently announced that the first patient has been dosed in its Phase 1 clinical trial of NMS-812 in adult...
by nms-sync | Jun 29, 2022 | News
The Board of Directors of NMS Group S.p.A has approved today the company’s annual financial report, including the consolidated financial statements of the Group as of 31 December 2021.
“2021 was a challenging yet rewarding year for our Group. As we firmly believe...
by nms-sync | May 13, 2022 | News
Nerviano, 13 May 2022
MPS1, also known as monopolar spindle 1, is a protein kinase which is over-expressed and hyperactivated in different tumors and which plays a critical role in the control of mitosis (cell division) by regulating a process called the...
by nms-sync | May 5, 2022 | News
Nerviano, 5 May 2022
Nerviano Medical Sciences (NMS Srl,) a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancers, today announces the new organizational structure and key appointments...
by nms-sync | Feb 7, 2022 | News
Nerviano, 7 February 2022
NMS Group, the center of excellence of oncology research and development in the heart of the Lombardy region is honored to receive the visit by Ms. Isabella Tovaglieri, Member of the European Parliament, Mr. Emanuele Monti, Chairman of...
by nms-sync | Jan 17, 2022 | News
Nerviano, 17 January 2022
The Shareholders’ Meeting of NMS Group S.p.A. (the “Company”) has appointed new Board of Directors for a three-year term. Tak-Wai (David) Wong has been named Chairman of the Board. Other newly appointed board members are...
Welcome and Check out our new motion picture!
Recent Comments